Oehninger S, Sueldo C, Lanzendorf S, Mahony M, Burkman L J, Alexander N J, Hodgen G D
Jones Institute for Reproductive Medicine, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk 23507.
Hum Reprod. 1994 Jul;9(7):1322-7. doi: 10.1093/oxfordjournals.humrep.a138702.
The objective of these studies was to evaluate the modulatory effect(s) of progesterone on sperm functions crucial to fertilization in infertile men with abnormal sperm parameters. A prospective, controlled study applying a sequential diagnostic analysis capable of identifying specific dysfunctions of the male gamete was performed. Patients (n = 14) were allocated to the study group if they had a history of infertility of > 1 year duration and after semen evaluation showed teratozoospermia (< 14% normal sperm forms as diagnosed by strict criteria) or terato-asthenozoospermia (< 50% progressive motility). After swim-up separation of the motile sperm fraction, the following functions were assessed with and without previous exposure to progesterone (1.0 micrograms/ml): acrosome reaction (using Pisum sativum agglutinin), hyperactivated motility (using a computerized semen analyser), sperm-zona pellucida binding (in the hemizona assay), sperm-zona pellucida penetration (in a sperm-zona penetration assay), and sperm-oocyte penetration (using the hamster zona-free oocyte/sperm penetration assay). Progesterone did not affect the percentage of acrosome-reacted spermatozoa after 1 or 3 h of incubation. Hyperactivated motility was significantly enhanced by progesterone after 1 h (12 +/- 4 versus 6 +/- 2% in controls; P < 0.02). Although progesterone did not affect sperm-zona binding, it significantly enhanced both sperm-zona pellucida penetration (27 versus 12% in controls; P = 0.03) and sperm-oocyte penetration (15 versus 8% in controls; P < 0.05). Because those sperm functions enhanced by progesterone are crucial to fertilization, the steroid may have value in the treatment of some male-factor patients undergoing assisted reproductive therapy.
这些研究的目的是评估孕酮对精子参数异常的不育男性受精关键精子功能的调节作用。进行了一项前瞻性对照研究,采用能够识别雄配子特定功能障碍的序贯诊断分析。患者(n = 14)如果有超过1年的不育病史,且精液评估显示为畸形精子症(按照严格标准诊断,正常精子形态<14%)或畸形-弱精子症(进行性运动精子<50%),则被分配到研究组。在对活动精子部分进行上浮分离后,在有或没有预先暴露于孕酮(1.0微克/毫升)的情况下评估以下功能:顶体反应(使用豌豆凝集素)、超激活运动(使用计算机化精液分析仪)、精子-透明带结合(在半透明带试验中)、精子-透明带穿透(在精子-透明带穿透试验中)以及精子-卵母细胞穿透(使用仓鼠无透明带卵母细胞/精子穿透试验)。孵育1小时或3小时后,孕酮不影响顶体反应精子的百分比。孵育1小时后,孕酮显著增强超激活运动(对照组为6±2%,处理组为12±4%;P<0.02)。虽然孕酮不影响精子与透明带的结合,但它显著增强了精子-透明带穿透(对照组为12%,处理组为27%;P = 0.03)和精子-卵母细胞穿透(对照组为8%,处理组为15%;P<0.05))。由于孕酮增强的那些精子功能对受精至关重要,这种类固醇可能对一些接受辅助生殖治疗的男性因素患者具有治疗价值。